India accounts for 1 in 7 adults living with diabetes globally. An estimated 89.8 million adults aged 20-79 years in India ...

Participants were randomly assigned to receive either dapagliflozin 10 mg daily or placebo for 12 months. Patients were ...

A new clinical trial shows that combining dapagliflozin with insulin improves kidney health and blood sugar control, and ...

Combining insulin treatment with the investigational drug dapagliflozin may improve health outcomes for adolescents with type ...

On 21 July 2025, the Court of Appeal delivered a significant ruling in AstraZeneca AB & Anor v Generics (UK) Limited & Ors, ...

Combining insulin treatment with the investigational drug dapagliflozin may improve health outcomes for adolescents with type 1 diabetes, according to ...

This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy ...

The majority of patients with heart failure who qualified for sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy did ...

The data from 2019 to 2023 show rapid uptake of the drugs alongside wide patient- and practice-level variations.

No increased risk of thrombotic events identified despite rise in erythrocytosis among sodium-glucose cotransporter 2 ...

Understand how a combined therapy shows significant nerve and glucose improvements in diabetic neuropathy, without added safety risks.

Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...